SFTPD and COVID-19: Elevated serum SP-D levels have been proposed as a biomarker for the severity of COVID-19, since patients with severe COVID-19 pneumonia exhibited increased plasma levels of SP-D gradually decreasing in the course of recovery period (Tong et al., 2021).